Display Settings:

Format

Send to:

Choose Destination
J Clin Pathol. 2000 Dec;53(12):890-2.

Recommendations for HER2 testing in the UK.

Author information

  • 1Department of Histopathology, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK. ian.ellis@nottingham.ac.uk

Abstract

Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.

PMID:
11265171
[PubMed - indexed for MEDLINE]
PMCID:
PMC1731136
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk